CPHI 2025: ProBiotix Health to feature probiotic-based menopause formulations
Key takeaways
- At CPHI 2025, ProBiotix Health will showcase its probiotic formulations designed to relieve symptoms and promote long-term cardiovascular health in women in menopause.
- The company’s formulations address long-term risks like heart disease and raised cholesterol, not just short-term symptoms.
- ProBiotix aims to expand probiotics’ role from digestive health to cardiometabolic and healthy aging.
ProBiotix Health will present its range of probiotics for menopause at the upcoming CPHI trade show in Frankfurt, Germany (October 28–30). Making its debut at the nutraceutical and pharma event, the company will showcase its YourBiotix formulations designed to support symptom relief and long-term cardiovascular health.
The company says it created its YourBiotixMH and YourBiotixPMH formulations for menopause and postmenopause health to reshape the conversation around menopause, moving from short-term relief to long-term health outcomes for women in menopause.
“It is estimated that by the end of 2025, 1.1 billion women worldwide will be transitioning through menopause, facing health and wellness challenges that are both physical and emotional. Science shows that postmenopausal women are five times more likely to suffer a heart attack, while 77% of women aged 45 and above have raised cholesterol,” says Steen Andersen, chief operating officer at ProBiotix Health.
“Most menopause supplements focus on symptom relief, such as hot flushes and sleep disturbance, without targeting these deeper, long-term risks. ProBiotix Health’s new formulations aim to close this gap by supporting women’s health during this important life stage.”
Probiotics for symptom relief
The YourBiotix formulations feature the company’s clinically validated probiotic strain Lactobacillus plantarum (LPLDL), in combination with nutrients that support positive menopause outcomes, like isoflavones, thiamine, and vitamins D and B6.

The supplements focus on relieving symptoms and addressing long-term cardiovascular and bone health risks that accompany menopause.
“This dual focus positions these two products as true next-generation solutions that will allow women to add life to years, not just years to life,” explains Andersen.
“As our awareness of menopause, not just as a transition but as a turning point in women’s long-term health, continues to grow, we are moving beyond symptom management to deliver solutions that safeguard women’s future well-being.”
The company’s product launches are part of its strategy to move probiotics beyond their traditional role in digestive health.
“The YourBiotix range of finished products reflects our mission to redefine probiotics as powerful tools in cardiometabolic health and healthy aging and bring real innovation to areas of health and wellness where it is needed most,” concludes Andersen.
ProBiotix Health will showcase its probiotic-based formulations at booth 4.1 B62. In addition to its menopause solutions, it will showcase probiotics for cholesterol health, vascular health, and blood pressure reduction.